Mallinckrodt PLC Company Profile (NYSE:MNK)

About Mallinckrodt PLC (NYSE:MNK)

Mallinckrodt PLC logoMallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:MNK
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.64048 billion
  • Outstanding Shares: 99,347,000
Average Prices:
  • 50 Day Moving Avg: $43.52
  • 200 Day Moving Avg: $46.37
  • 52 Week Range: $38.80 - $85.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 5.65
  • P/E Growth: 1.12
Sales & Book Value:
  • Annual Revenue: $3.31 billion
  • Price / Sales: 1.42
  • Book Value: $51.45 per share
  • Price / Book: 0.92
  • EBIDTA: $744.3 million
  • Net Margins: 16.01%
  • Return on Equity: 16.33%
  • Return on Assets: 5.48%
  • Debt-to-Equity Ratio: 1.11%
  • Current Ratio: 1.40%
  • Quick Ratio: 1.05%
  • Average Volume: 2.16 million shs.
  • Beta: 1.52
  • Short Ratio: 8.23

Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)

What is Mallinckrodt PLC's stock symbol?

Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt PLC's stock buyback program work?

Mallinckrodt PLC declared that its board has authorized a share repurchase plan on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy up to 18.5% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board believes its shares are undervalued.

How were Mallinckrodt PLC's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) posted its earnings results on Monday, May, 8th. The company reported $1.68 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.63 by $0.05. The business earned $810.90 million during the quarter, compared to analysts' expectations of $781.23 million. Mallinckrodt PLC had a net margin of 16.01% and a return on equity of 16.33%. Mallinckrodt PLC's revenue was down .6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 earnings per share. View Mallinckrodt PLC's Earnings History.

Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?

17 brokers have issued 12 month price objectives for Mallinckrodt PLC's stock. Their predictions range from $52.00 to $98.00. On average, they expect Mallinckrodt PLC's share price to reach $76.38 in the next twelve months. View Analyst Ratings for Mallinckrodt PLC.

What are analysts saying about Mallinckrodt PLC stock?

Here are some recent quotes from research analysts about Mallinckrodt PLC stock:

  • 1. According to Zacks Investment Research, "Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to lingering challenging conditions for quite some time. The company also sold its Intrathecal Therapy business to focus on its key areas. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Weakness in shares persist as shares have underperformed the Medical-Generic Drugs industry so far in 2017. On the other hand, Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments. The company is working on expanding Acthar's label further." (7/11/2017)
  • 2. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
  • 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)

Who are some of Mallinckrodt PLC's key competitors?

Who are Mallinckrodt PLC's key executives?

Mallinckrodt PLC's management team includes the folowing people:

  • Melvin D. Booth Ph.D., CPA, Independent Chairman of the Board
  • Mark C. Trudeau, President, Chief Executive Officer, Director
  • Matthew K. Harbaugh, Chief Financial Officer, Senior Vice President
  • Ian J. Watkins, Chief Human Resource Officer, Senior Vice President
  • Steve Romano, Senior Vice President, Chief Scientific Officer
  • Raymond J. Furey, Senior Vice President, Chief Compliance Officer
  • Terrance L. Carlson, Senior Vice President and General Counsel - Interim
  • Meredith B. Fischer, Senior Vice President - Communications and Public Affairs
  • Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases
  • Gary M. Phillips M.D., Senior Vice President and Chief Strategy Officer

Who owns Mallinckrodt PLC stock?

Mallinckrodt PLC's stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Quadrant L P CA (0.23%), APG Asset Management N.V. (0.12%), Meyer Handelman Co. (0.10%), Chevy Chase Trust Holdings Inc. (0.09%), First National Bank of Omaha (0.06%) and Oregon Public Employees Retirement Fund (0.05%). Company insiders that own Mallinckrodt PLC stock include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Institutional Ownership Trends for Mallinckrodt PLC.

Who sold Mallinckrodt PLC stock? Who is selling Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, APG Asset Management N.V., Nisa Investment Advisors LLC, Bank of Montreal Can, Eqis Capital Management Inc., Exxonmobil Investment Management Inc. TX, US Bancorp DE and Chevy Chase Trust Holdings Inc.. View Insider Buying and Selling for Mallinckrodt PLC.

Who bought Mallinckrodt PLC stock? Who is buying Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was purchased by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., Polianta Ltd, Aperio Group LLC, Oregon Public Employees Retirement Fund, Meyer Handelman Co., Denali Advisors LLC, Creative Planning and LS Investment Advisors LLC. Company insiders that have bought Mallinckrodt PLC stock in the last two years include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Insider Buying and Selling for Mallinckrodt PLC.

How do I buy Mallinckrodt PLC stock?

Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt PLC's stock price today?

One share of Mallinckrodt PLC stock can currently be purchased for approximately $47.42.

MarketBeat Community Rating for Mallinckrodt PLC (NYSE MNK)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  474 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  715
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $76.38 (61.08% upside)

Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/16/2017Piper Jaffray CompaniesSet Price TargetBuy$85.00MediumView Rating Details
7/17/2017Canaccord GenuitySet Price TargetBuy$87.00MediumView Rating Details
6/21/2017Wells Fargo & CompanyReiterated RatingOutperform$83.50HighView Rating Details
6/20/2017Jefferies Group LLCReiterated RatingBuy$70.00HighView Rating Details
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$52.00LowView Rating Details
5/31/2017Morgan StanleySet Price TargetBuy$65.00LowView Rating Details
5/31/2017Deutsche Bank AGSet Price TargetBuy$68.00LowView Rating Details
5/31/2017MizuhoReiterated RatingBuy$73.00LowView Rating Details
5/10/2017BMO Capital MarketsLower Price TargetOutperform$79.00 -> $69.00MediumView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
1/25/2017J P Morgan Chase & CoSet Price TargetHold$78.00N/AView Rating Details
1/19/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$72.00N/AView Rating Details
11/18/2016Raymond James Financial, Inc.Initiated CoverageOutperform$72.00N/AView Rating Details
8/26/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$83.00N/AView Rating Details
8/25/2016Barclays PLCReiterated RatingOverweight$88.00N/AView Rating Details
8/12/2016Stifel NicolausInitiated CoverageBuy$95.00N/AView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00N/AView Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00N/AView Rating Details
10/7/2015Bank of America CorporationLower Price TargetBuy$135.00 -> $131.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Mallinckrodt PLC (NYSE:MNK)
Earnings by Quarter for Mallinckrodt PLC (NYSE:MNK)
Earnings History by Quarter for Mallinckrodt PLC (NYSE MNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
2017 EPS Consensus Estimate: $7.58
2018 EPS Consensus Estimate: $8.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.54$1.84$1.71
Q2 20173$1.70$1.95$1.80
Q3 20173$1.88$1.96$1.91
Q4 20173$2.02$2.35$2.16
Q1 20183$1.82$2.06$1.93
Q2 20181$2.09$2.09$2.09
Q3 20181$2.03$2.03$2.03
Q4 20181$2.48$2.48$2.48
(Data provided by Zacks Investment Research)


Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE:MNK)
Insider Ownership Percentage: 0.77%
Institutional Ownership Percentage: 96.37%
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt PLC (NYSE:MNK)
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Steven J. RomanoVPBuy1,000$39.88$39,880.00View SEC Filing  
6/8/2017Hugh M. O'neillVPBuy1,000$40.24$40,240.00View SEC Filing  
6/5/2017Coleman N Lannum IIIVPBuy500$39.33$19,665.00View SEC Filing  
6/2/2017Coleman N Lannum IIIVPBuy1,350$42.89$57,901.50View SEC Filing  
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mallinckrodt PLC (NYSE:MNK)
Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
DateHeadline logoMallinckrodt triples its spending on lobbying - July 22 at 6:31 AM logoMallinckrodt: A Crowded Short Where The Bear Thesis Is Falling Apart - Seeking Alpha - July 20 at 1:19 AM logoMallinckrodt's StrataGraft qualifies for accelerated review in US - Seeking Alpha - July 20 at 1:19 AM logoU.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced Therapy - July 18 at 11:35 PM logoPiper Jaffray Companies Analysts Give Mallinckrodt PLC (NYSE:MNK) a $85.00 Price Target - July 17 at 11:42 PM logoMallinckrodt PLC (MNK) to Post FY2017 Earnings of $7.51 Per Share, Oppenheimer Holdings Forecasts - July 17 at 9:36 AM logo$827.43 Million in Sales Expected for Mallinckrodt PLC (NYSE:MNK) This Quarter - July 16 at 8:08 AM logoFTC Approves Sublicense for Synacthen Depot Submitted by Mallinckrodt ARD Inc. (MNK) - - July 15 at 6:32 AM logoMallinckrodt (MNK) Phase 3 Terlipressin Trial Enrollment Ahead of ... - - July 15 at 6:32 AM logoETFs with exposure to Mallinckrodt Plc : July 14, 2017 - July 15 at 6:32 AM logo$1.72 EPS Expected for Mallinckrodt PLC (NYSE:MNK) This Quarter - July 14 at 6:30 PM logoBrokers Offer Predictions for Mallinckrodt PLC's Q2 2017 Earnings (MNK) - July 14 at 9:27 AM logoMallinckrodt (MNK) Phase 3 Terlipressin Trial Enrollment Ahead of Schedule - July 14 at 6:31 AM logoPharma Company Reaches Record Settlement With Feds Over Alleged Role In Opioid Epidemic - July 14 at 6:31 AM logoMallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of Schedule - July 14 at 6:31 AM logoMallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD - July 14 at 6:31 AM logoMallinckrodt (MNK) Announces FDA Orphan Drug Designation for Potential Treatment of DMD - July 13 at 6:53 AM logoMallinckrodt to Pay $35M for Controlled Substances Probe - July 13 at 6:53 AM logoFDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne Muscular Dystrophy - July 13 at 6:53 AM logoMallinckrodt gets special FDA status for experimental muscular dystrophy drug - July 13 at 6:53 AM logoMallinckrodt Finalizes Previously Announced Agreement with DEA and USAOs - July 12 at 3:49 AM logoMallinckrodt settles U.S. opioid drug probe for $35 million - July 12 at 3:49 AM logoMallinckrodt PLC (MNK) Cut to "Sell" at Zacks Investment Research - July 11 at 4:10 PM logoAnalyzing Mallinckrodt PLC (NYSE:MNK) & Advanced Accelerator Applications (AAAP) - July 11 at 12:21 AM logoMallinckrodt Plc breached its 50 day moving average in a Bearish Manner : MNK-US : July 7, 2017 - July 8 at 12:40 PM logoTechnical Snapshots for These Generic Drugs Stocks -- Mallinckrodt, Patheon, Zoetis, and Innocoll - July 7 at 7:29 AM logoMallinckrodt PLC to Post FY2017 Earnings of $7.40 Per Share, Cantor Fitzgerald Forecasts (MNK) - July 6 at 9:16 AM logoMallinckrodt Announces Specialty Brands Investor Briefing - July 5 at 8:44 PM logoMallinckrodt PLC (MNK) Given Average Recommendation of "Buy" by Analysts - July 4 at 9:18 AM logoMallinckrodt plc To Report Earnings Results for Second Quarter of Fiscal 2017 - June 30 at 1:42 AM logoAnalyst: Mallinckrodt Investors Seem To Be Pricing In Extreme Issues For Acthar - June 30 at 1:41 AM logoWells Fargo & Company Reiterates Outperform Rating for Mallinckrodt PLC (MNK) - June 25 at 1:52 PM logoAndrew Left Predicts Eventual DOJ Prosecution Of Mallinckrodt For Selling HP Acthar Without Proven Efficacy - Benzinga - June 23 at 8:05 AM logoThere's frightening new data on the effects of a blockbuster drug Wall Street loves to hate - June 23 at 8:05 AM logoHealth Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and Opinion - June 23 at 8:05 AM logoAndrew Left Predicts Eventual DOJ Prosecution Of Mallinckrodt For Selling HP Acthar Without Proven Efficacy - June 22 at 12:44 PM logoMallinckrodt PLC (MNK) Expected to Post Quarterly Sales of $827.43 Million - June 22 at 10:28 AM logoMallinckrodt (MNK): Unlikely To Trip A Debt Covenant - Wells Fargo - - June 21 at 7:45 PM logoMallinckrodt Plc breached its 50 day moving average in a Bullish Manner : MNK-US : June 20, 2017 - June 20 at 7:36 PM logoCheck out how the shorts have been piling into Wall Street's most hated pharma stock - June 20 at 7:36 PM logo$1.73 EPS Expected for Mallinckrodt PLC (MNK) This Quarter - June 20 at 4:12 PM logoMallinckrodt PLC's (MNK) "Buy" Rating Reiterated at Jefferies Group LLC - June 20 at 11:08 AM logoETFs with exposure to Mallinckrodt Plc : June 19, 2017 - June 19 at 5:40 PM logoA Wall Street investor call revealed part of the secret of why drugs are so expensive - June 19 at 11:30 AM logoIs Mallinckrodt (MNK) a Great Stock for Value Investors? - June 19 at 11:30 AM logoUPDATE: Cantor Fitzgerald Starts Mallinckrodt plc (MNK) at ... - - June 17 at 12:33 AM logoMallinckrodt Plc :MNK-US: Earnings Analysis: Q2, 2017 By the Numbers : June 16, 2017 - June 16 at 7:33 PM logoMallinckrodt PLC (MNK) Receives New Coverage from Analysts at Cantor Fitzgerald - June 16 at 10:06 AM logoMallinckrodt (MNK) Enrolls First Patient in Phase 2B Trial of HP Acthar Gel for ALS - - June 14 at 10:14 PM logoMallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS) - June 14 at 10:14 PM



Mallinckrodt PLC (MNK) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff